Safety and Efficacy of Self-Administered Subcutaneous Immunoglobulin in Patients with Primary Immunodeficiency Diseases
Tóm tắt
Từ khóa
Tài liệu tham khảo
Björkander J, Chapel H, Spickett G: Comparison of the efficacy and safety of immunoglobulin given subcutaneously versus intravenous immunoglobulin in the prevention of infection in patients with primary antibody deficiency syndromes. Mol Immunol 35:11–12, 1998.
Cunningham-Rundles C, Siegel F, Smithwick E, Lion-Boule A, Cunningham-Rundles S, O’Malley J: Efficacy of intravenous immunoglobulin in primary humoral immunodeficiency disease. Ann Intern Med 101:435–439, 1984.
Lederman H, Roifman C, Lavi S, Gelfand E: Corticosteroids for prevention of adverse reactions to intravenous immune globulin infusions, in hypogammaglobulinemic patients. Am J Med 81:443–446, 1986.
Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA: Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 273:1865–1870, 1995.
Bertorini TE, Nance AM, Horner LH, Greene W, Gelfand MS, Jaster JH: Complications of intravenous gammaglobulin in neuromuscular and other diseases. Muscle Nerve 19:388–391, 1996.
Brannagan TH, 3rd, Nagle KJ, Lange DJ, Rowland LP: Complications of intravenous immune globulin treatment in neurologic disease. Neurology 47:674–677, 1996.
Immune Deficiency Foundation 2003, posting date. Treatment experiences and preferences of patients with primary immune deficiency disease: First national survey. [Online.]
Berger M, Cupps TR, Fauci AS: Immunoglobulin replacement therapy by slow subcutaneous infusion. Ann Intern Med 93:55–56, 1980
Chapel HM, Spickett GP, Ericson D, Engl W, Eibl MM, Bjorkander J: The comparison of the efficacy and safety of intravenous versus subcutaneous immunoglobulin replacement therapy. J Clin Immunol 20:94–100, 2000.
Gardulf A, Hammarstrom L, Smith CI: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338:162–166, 1991
Gardulf A, Bjorvell H, Gustafson R, Hammarstrom L, Smith CI: The life situations of patients with primary antibody deficiency untreated or treated with subcutaneous gammaglobulin infusions. Clin Exp Immunol 92:200–204, 1993.
Gardulf A, Hammarstrom L: Subcutaneous administration of immunoglobulins: What are the advantages? Clin Immunother 6:108–116, 1996.
Gardulf A, Andersen V, Bjorkander J, Ericson D, Froland SS, Gustafson R, Hammarstrom L, Jacobsen MB, Jonsson E, Moller G, et al.: Subcutaneous immunoglobulin replacement in patients with primary antibody deficiencies: Safety and costs. Lancet 345:365–369, 1995.
Gardulf A, Nicolay U, Math D, Asensio O, Bernatowska E, Bock A, Costa-Carvalho BT, Granert C, Haag S, Hernandez D, Kiessling P, Kus J, Matamoros N, Niehues T, Schmidt S, Schulze I, Borte M: Children and adults with primary antibody deficiencies gain quality of life by subcutaneous IgG self-infusions at home. J Allergy Clin Immunol 114:936–942, 2004.
Nicolay U, Kiessling P, Berger M, Gupta S, Yel L, Roifman CM, Gardulf A, Eichmann F, Haag S, Massion C, Ochs HD: Health-related quality of life and treatment satisfaction in north american patients with primary immunedeficiency diseases receiving subcutaneous IgG self-infusions at home. J Clin Immunol 26:65–72, 2006.
Ochs HD, Pinciaro PJ: Octagam 5%, an intravenous IgG product, is efficacious and well tolerated in subjects with primary immunodeficiency diseases. J Clin Immunol 24:309–314, 2004.
Berger M: Subcutaneous immunoglobulin replacement in primary immunodeficiencies. Clin Immunol 112:1–7, 2004.
Eijkhout HW, van Der Meer JW, Kallenberg CG, Weening RS, van Dissel JT, Sanders LA, Strengers PF, Nienhuis H, Schellekens PT: The effect of two different dosages of intravenous immunoglobulin on the incidence of recurrent infections in patients with primary hypogammaglobulinemia. A randomized, double-blind, multicenter crossover trial. Ann Intern Med 135:165–174, 2001.
Gardulf A, Nicolay U, Asensio O, Bernatowska E, et al.: Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies—a prospective, multi-national study. J Clin Immunol In press, 2006.
Pruzanski W, Sussman G, Dorian W, Van T, Ibanez D, Redelmeier D: Relationship of the dose of intravenous gammaglobulin to the prevention of infections in adults with common variable immunodeficiency. Inflammation 20:353–359, 1996.
Gaspar J, Gerritsen B, Jones A: Immunoglobulin replacement treatment by rapid subcutaneous infusion. Arch Dis Child 79:48–51, 1998.
Burks AW, Sampson HA, Buckley RH: Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulinemia. Detection of IgE antibodies to IgA. N Engl J Med 314:560–564, 1986.
Sundin U, Nava S, Hammarstrom L: Induction of unresponsiveness against IgA in IgA-deficient patients on subcutaneous immunoglo-bulin infusion therapy. Clin Exp Immunol 112:341–346, 1998.
Eijkhout HW, van den Broek PJ, van der Meer JW: Substitution therapy in immunodeficient patients with anti-IgA antibodies or severe adverse reactions to previous immunoglobulin therapy. Neth J Med 61:213–217, 2003.
Berger M, Pinciaro PJ: Safety, efficacy, and pharmacokinetics of Flebogamma 5% [immune globulin intravenous (human)] for replacement therapy in primary immunodeficiency diseases. J Clin Immunol 24:389–396, 2004.
Ochs HD, Fischer SH, Wedgwood RJ, Wara DW, Cowan MJ, Ammann AJ, Saxon A, Budinger MD, Allred RU, Rousell RH: Comparison of high-dose and low-dose intravenous immunoglobulin therapy in patients with primary immunodeficiency diseases. Am J Med 76:78–82, 1984.